Shionogi (Pharmaceutical Brands) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

  • Investments
  • 3

Shionogi (Pharmaceutical Brands) General Information

Description

Portfolio of four pharmaceutical brands. The portfolio includes four brand pharmaceutical products Triglide Tablets, Robinul and Robinul Forte Tablets, Furadantin Suspension and Fexmid Tablets.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 3-1-8 Doshomachi
  • Chuo-Ku
  • Osaka, 541-0045
  • Japan
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Corporate Office
  • 3-1-8 Doshomachi
  • Chuo-Ku
  • Osaka, 541-0045
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shionogi (Pharmaceutical Brands) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shionogi (Pharmaceutical Brands)‘s full profile, request access.

Request a free trial

Shionogi (Pharmaceutical Brands) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shionogi (Pharmaceutical Brands)‘s full profile, request access.

Request a free trial

Shionogi (Pharmaceutical Brands) Investments (3)

Shionogi (Pharmaceutical Brands)’s most recent deal was a Later Stage VC with Reborna Biosciences for . The deal was made on 25-May-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Reborna Biosciences 25-May-2023 Later Stage VC Drug Discovery
Reborna Biosciences 14-Oct-2021 Later Stage VC Drug Discovery
Avita 07-Sep-2021 Seed Round IT Consulting and Outsourcing
To view Shionogi (Pharmaceutical Brands)’s complete investments history, request access »

Shionogi (Pharmaceutical Brands) Exits (2)

Shionogi (Pharmaceutical Brands)’s most recent exit was on 25-May-2023 from Reborna Biosciences. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Reborna Biosciences 25-May-2023 Completed
  • 4 buyers
Reborna Biosciences 14-Oct-2021 Later Stage VC Completed
To view Shionogi (Pharmaceutical Brands)’s complete exits history, request access »

Shionogi (Pharmaceutical Brands) FAQs

  • Where is Shionogi (Pharmaceutical Brands) headquartered?

    Shionogi (Pharmaceutical Brands) is headquartered in Osaka, Japan.

  • What industry is Shionogi (Pharmaceutical Brands) in?

    Shionogi (Pharmaceutical Brands)’s primary industry is Buildings and Property.

  • Is Shionogi (Pharmaceutical Brands) a private or public company?

    Shionogi (Pharmaceutical Brands) is a Private company.

  • What is Shionogi (Pharmaceutical Brands)’s current revenue?

    The current revenue for Shionogi (Pharmaceutical Brands) is .

  • Who are Shionogi (Pharmaceutical Brands)’s investors?

    Shionogi has invested in Shionogi (Pharmaceutical Brands).

  • When was Shionogi (Pharmaceutical Brands) acquired?

    Shionogi (Pharmaceutical Brands) was acquired on 08-Jan-2016.

  • Who acquired Shionogi (Pharmaceutical Brands)?

    Shionogi (Pharmaceutical Brands) was acquired by Casper Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process